Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Cediranib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 18 Oct 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 07 Oct 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.